Related Experiment Video
Updated: May 9, 2025
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
Published on: April 27, 2021
Paeoniflorin as a potential agent for urticaria treatment: Suppressing mast cell degranulation through
Xurui Wang1, Anjing Chen2, Yaobin Pang2
1Department of Chinese Medicine Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Introduction:
Paeoniflorin (PF) has strong immunomodulatory effects and has been widely used in the treatment of many diseases, but its mechanism of action in urticaria is not clear. The aim of this experiment was to investigate the role and mechanism of paeoniflorin in improving mast cell degranulation in urticaria.
Methods:
The mouse model of urticaria was replicated by ovalbumin+ aluminum hydroxide method, and the mast cell degranulation model was induced by anti-DNP IgE+ Dinitrophenyl- Bovine Serum Albumin (DNP-BSA), and the mice and cells were intervened by different doses of PF. The histopathological changes of the dorsal skin were observed using hematoxylin-eosin (HE) staining, the infiltration of mast cells was observed by Toluidine blue staining, the expression of mast cell tryptase (MCT) was examined by Immunohistochemical staining, the cell viability was detected by CCK8 assay, and Rhod-2/AM flow cytometry assay to determine calcium ion content, enzyme-linked immunosorbent assay (ELISA) detected mast cell degranulation-associated factors, and Western blot analyzed HMGB1/TLR4/NF-κB signaling factors.
Results:
PF reduced the number of scratches in mice, ameliorated histopathological damage in dorsal skin, decreased mast cell degranulation rate, reduced the levels of Ca2 +, MCT, β-HEX, HIS, MCP-1, TNF-α, and IL-13, and inhibited the expression of HMGB1, TLR4, MyD88, NF-κB p65 (Nucleus), and p-IκBα. Moreover, Rec-HMGB1 reversed the effect of PF.
Conclusion:
PF mitigates urticarial mast cell degranulation through the inhibition of the HMGB1/TLR4/NF-κB signaling pathway, suggesting its potential as a therapeutic agent for the treatment of urticaria.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
02:06Allergic Reactions
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...